CN104531856A - 胃癌进展及预后相关分子标志物miR-1258 - Google Patents
胃癌进展及预后相关分子标志物miR-1258 Download PDFInfo
- Publication number
- CN104531856A CN104531856A CN201410791924.8A CN201410791924A CN104531856A CN 104531856 A CN104531856 A CN 104531856A CN 201410791924 A CN201410791924 A CN 201410791924A CN 104531856 A CN104531856 A CN 104531856A
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- prognosis
- mir
- cancer
- molecular marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及胃癌根治术后预后诊断领域,具体来说涉及一种胃癌疾病进展分子标志物miR-1258,其可应用于在胃癌术后早期进行预后评估。MiR-1258在胃癌组织中明显低表达并与胃癌侵袭深度及淋巴管癌栓显著相关,尤为重要的是miR-1258表达量低的患者预后较差。本发明还提供了一种诊断胃癌进展及预后的试剂盒。使用本发明的胃癌进展与预后相关分子标志物miR-1258诊断胃癌患者术后进展及评估其生存,可给患者及时有效地随访、治疗等干预措施,以延长生存时间,提高生存质量。该发明的试剂盒具有操作简单,安全无创伤,高特异性,高灵敏性以及易于大量筛查的特点。
Description
技术领域
本发明涉及胃癌根治术后预后诊断领域,具体来说涉及一种胃癌疾病进展分子标志物miR-1258,其可应用于在胃癌术后早期进行预后评估。
背景技术
胃癌是我国发病率和死亡率均居前列的恶性肿瘤。近年来,随着多学科综合治疗的推广,胃癌治疗水平有所提高。然而,进展期胃癌根治术后5年生存率长期徘徊在30%-50%,转移扩散是其预后不良的首要原因。因此,深入探索胃癌发生及转移机制,寻找转移高危个体预测和早期诊断的分子标志,确立新的治疗靶点对提高胃癌疗效具有特殊的重要意义。
MicroRNA (miRNA) 是一类长度约为22核苷酸的非编码单链小分子RNA,转录和加工成熟后,可与靶基因mRNA的3’端非翻译区互补结合,降解mRNA或抑制其翻译。MiRNA具有高度的保守性、时序性和组织特异性,目前已被证实其在个体发育、细胞分化、增殖、凋亡等生理活动中以及在肿瘤发生、发展等病理过程中起重要调控作用。
近年来的研究表明,胃癌预后与miRNA密切相关,miRNA可以通过作用于靶基因从而影响胃癌进展,因此miRNA对胃癌预后评估也可能有相应的作用。
发明内容
发明目的:本发明提供了一种新的与胃癌疾病进展相关的miRNA,可应用于在胃癌术后早期进行预后评估,以给患者及时有效地随访、治疗等干预措施,延长生存时间。
技术方案:该miRNA为miR-1258,其序列:5’-AGUUAGGAUUAGGUCGUGGAA -3’(MIMAT0005909) (SEQ ID NO:1)。
发明人发现,与癌旁非癌组织相比较,miR-1258在105对胃癌组织中明显低表达并与胃癌侵袭深度及淋巴管癌栓显著相关,尤为重要的是miR-1258表达量低的患者预后较差。由此可见,miR-1258的异常低表达与胃癌进展及预后密切相关。
在上述发现的基础上,本发明提供了miR-1258在制备评估胃癌进展及预后的诊断试剂中的用途。
具体地,所述诊断试剂通过检测胃癌患者手术标本癌组织及癌旁非癌组织中miR-1258的表达量,并与临床病理因素、预后进行分析,发现miR-1258在105对胃癌组织中明显低表达并与胃癌侵袭深度及淋巴管癌栓显著相关,尤为重要的是miR-1258表达量低的患者预后较差。在一个特定的实施方案中,使用定量PCR的方法检测胃癌患者术后标本癌组织及癌旁非癌组织中miR-1258的表达量。
本发明还提供了一种诊断胃癌进展及预后的诊断试剂盒,其包括:
(1)组织中总RNA提取试剂,
(2)RNA加polyA尾试剂,
(3)纯化RNA试剂,
(4)反转录试剂,
(5)定量PCR试剂,
其中,反转录试剂中包含RT-Primer
5’-GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTA-3’(SEQ ID NO:2);
5’-GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTC-3’(SEQ ID NO:3);
5’-GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTG-3’(SEQ ID NO:4)。
定量PCR试剂包含胃癌进展与预后相关分子标志物miR-1258的特异性引物
miR-1258:5’-AGTTAGGATTAGGTCGTGGAAAA-3’(SEQ ID NO:5);
5’-GCTGTCAACGATACGCTACGT-3’(SEQ ID NO:6); U6:5’-Cgcttcggcagcacatatac-3’(SEQ ID NO:7);
5’-ttcacgaatttgcgtgtcat-3’(SEQ ID NO:8)。
使用本发明的胃癌进展与预后相关分子标志物miR-1258诊断胃癌患者术后进展及评估其生存,可给患者及时有效地随访、治疗等干预措施,以延长生存时间,提高生存质量。该发明的试剂盒具有操作简单,安全无创伤,高特异性,高灵敏性以及易于大量筛查的特点。
具体实施方式
1. 胃癌组织及癌旁非癌组织中mRNA提取
(1)收集中国医科大学附属第一医院肿瘤外科2007-2009年间胃癌根治术后标本,胃癌组织及癌旁非癌组织105对,分别置于1.5ml 的RNase/DNase-free 离心管中,经液氮桶转移至-80℃深低温冰箱保存。
(2)使用mRNA提取试剂盒(美国Ambion公司的mirVana miRNA Isolation Kit),从-80℃冰箱中迅速取出样本,切取适量的小块(50mg),立即投入置于冰上的裂解液中。使用电动匀浆器以3500转/分钟的转速对组织进行快速匀浆,时间为20-30秒。再经有机抽提,Glass-fiber洗脱,得到总RNA。
(3)提取的总RNA浓度测定及质量鉴定:取3μl RNA,使用Implen NanoPhotometer? P-Class测定浓度。取2μl RNA,在1%的agarose gel 中快速电泳,通过紫外凝胶成像仪拍照检测其完整性。
四步法定量检测胃癌组织及癌旁非癌组织中的miRNA
(1)加polyA 尾
应用加polyA 尾试剂盒(美国Ambion公司)在无RNA 酶的PCR管(Axygen 公司,200μl)中配制加polyA 尾的反应液,RNA模板5μg,体系为20μl。37℃水浴放置30分钟后置于冰上。
5μg总RNA加polyA尾反应体系
组分 | 加入量(μl) |
E-PAP (2 units/μL) | 1 |
5X E-PAP Buffer | 4 |
ATP Solution(10 mM) | 2 |
25 mM MnCl2 | 2 |
RNase Inhibitor | 1 |
RNA(5μg) | x |
Nuclease-free Water | 10-x |
总体积 | 20 |
(注:加入的RNA体积由RNA的浓度确定,x=5μg/RNA浓度)
(2)加polyA 尾后的RNA抽提纯化
向以上反应液中加入20μl的酚/氯仿/异戊醇(10μl/9.6μl/0.4μl),充分混匀。4℃,12000rpm离心10分钟,取上层水相转移至新无RNA 酶的PCR 管(Axygen 公司,200μl)。再经酚/氯仿萃取,3M醋酸钠及冰乙醇洗涤,用Nuclease-free Water 10μl将RNA重新溶解。取3μl RNA,使用Implen NanoPhotometer? P-Class测定浓度。
(3)反转录合成cDNA第一链:
使用美国Invitrogen公司的SuperScript First-Stand Synthesis System试剂盒。RNA模板4μg,体系为20μl。
ⅰ. 在无RNA 酶的PCR 管(Axygen 公司,200μl)中配制如下反应液(冰上操作),65℃孵育5分钟,立即放到冰上冰浴至少1分钟。
组分 | 加入量(μl) |
dNTP mix(10 mM) | 1 |
RT primer | 1 |
RNA(4μg) | x |
Nuclease-free Water | 8-x |
总体积 | 10 |
(注:RT primer为RT—primer1、RT—primer2、RT—primer3的混合物,加入的RNA体积由抽提后的RNA浓度确定,x=4μg/RNA浓度)
(注:上海生工生物技术有限公司合成)
ⅱ. 配置反转录反应液
组分 | 加入量(μl) |
SuperScriptTMⅢ RT | 1 |
10X RT Buffer | 2 |
25 mM MnCl2 | 4 |
0.1 M DTT | 2 |
RNase OUTTM | 1 |
总体积 | 20 |
ⅲ. 将ⅰ与ⅱ得到的溶液混合,50℃孵育50分钟后85℃保温5分钟。立即放到冰上,待离心后加入1μl RNase H,37℃孵育20分钟,置冰上冷却,得到cDNA。-20℃保存待用。
(4)qPCR 定量检测
使用美国Invitrogen公司的EXPRESS SYBR? GreenER? qPCR Supermix Universal,体系为25μl。在无RNA 酶的PCR 管(Axygen 公司,200μl)中配制如下反应液(冰上操作)
(注:以U6 RNA为内参,以上引物均由上海生工生物技术有限公司合成)
使用LightCycler 480 II系统(瑞士Roche公司)进行检测,程序设定如下:
温度 | 时间 | 循环数 |
95℃ | 30s | 1 |
95℃ | 5s | 45 |
56℃ | 30s | 45 |
(注:退火温度55-58℃,56℃最佳)
绘制溶解曲线,检查引物的特异性,程序设定为:95℃ 5s,60℃ 1min。
采用LightCycler 480 software release 1.5.1.62进行数据分析。
统计分析miR-1258与胃癌临床病理因素及预后的相关性
使用spss 16.0软件进行统计学分析。进行三次以上独立试验,所得数据使用平均数±标准差表示。使用t检验比较均值。对于miR-1258表达与临床病理因素相关性的研究,如病理因素是二分类变量,采用Mann-Whitney U检验,如为多分类变量,使用Kruskall-Wallis检验。单因素生存分析使用Log-rank检验,并绘制KM生存曲线,多因素生存分析采用Cox风险比例模型。所有统计结果均以P<0.05认为存在显著差异。
用上述方法可测得胃癌组织及癌旁非癌组织中的miR-1258的平均Ct值分别为14.18 ± 3.35 和11.51 ± 2.88,与非癌组织相比较,miR-1258在105对胃癌组织中明显低表达(P<0.001),并与胃癌侵袭深度(P = 0.023)及淋巴管癌栓(P = 0.017)显著相关。多因素生存分析结果显示,miR-1258表达量低的患者预后较差(P<0.001)。
<110> 王振宁
<120> 胃癌进展及预后相关分子标志物miR-1258
<160> 序列个数
<170> PatentIn version 3.3
<210>1
<211> 21
<212> RNA
<213>人工序列
<400> 1
AGUUAGGAUUAGGUCGUGGAA
<210>2
<211>61
<212> RNA
<213>人工序列
<400> 2
GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTA
<210>3
<211>61
<212> RNA
<213>人工序列
<400> 3
GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTC
<210>4
<211>61
<212> RNA
<213>人工序列
<400> 4
GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTG
<210>5
<211>23
<212> RNA
<213>人工序列
<400> 5
AGTTAGGATTAGGTCGTGGAAAA
<210>6
<211>21
<212> RNA
<213>人工序列
<400> 6
GCTGTCAACGATACGCTACGT
<210>7
<211>20
<212> RNA
<213>人工序列
<400> 7
Cgcttcggcagcacatatac
<210>8
<211>20
<212> RNA
<213>人工序列
<400> 8
ttcacgaatttgcgtgtcat。
Claims (2)
1.一种胃癌进展及预后相关分子标志物miR-1258,其序列为5’-AGUUAGGAUUAGGUCGUGGAA -3’(SEQ ID NO:1),其在制备评估胃癌进展及预后的诊断试剂中的应用。
2.一种如权利要求1所述的胃癌进展及预后相关分子标志物miR-1258的诊断试剂盒,其特征在于:其包括:
(1)组织中总RNA提取试剂,
(2)RNA加polyA尾试剂,
(3)纯化RNA试剂,
(4)反转录试剂,
(5)定量PCR试剂,
其中,反转录试剂中包含RT-Primer
5’-GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTA-3’(SEQ ID NO:2);
5’-GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTC-3’(SEQ ID NO:3);
5’-GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTTTTTTG-3’(SEQ ID NO:4);
定量PCR试剂包含胃癌进展与预后相关分子标志物miR-1258的特异性引物
miR-1258: 5’-AGTTAGGATTAGGTCGTGGAAAA-3’(SEQ ID NO:5);
5’-GCTGTCAACGATACGCTACGT-3’(SEQ ID NO:6);
U6: 5’-Cgcttcggcagcacatatac-3’(SEQ ID NO:7);
5’-ttcacgaatttgcgtgtcat-3’(SEQ ID NO:8)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410791924.8A CN104531856A (zh) | 2014-12-19 | 2014-12-19 | 胃癌进展及预后相关分子标志物miR-1258 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410791924.8A CN104531856A (zh) | 2014-12-19 | 2014-12-19 | 胃癌进展及预后相关分子标志物miR-1258 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104531856A true CN104531856A (zh) | 2015-04-22 |
Family
ID=52847475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410791924.8A Pending CN104531856A (zh) | 2014-12-19 | 2014-12-19 | 胃癌进展及预后相关分子标志物miR-1258 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104531856A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110577999A (zh) * | 2019-08-02 | 2019-12-17 | 上海交通大学 | 一种cxcr4作为胃癌预后评估生物标志物的应用及诊断试剂盒 |
CN111621573A (zh) * | 2020-07-27 | 2020-09-04 | 江苏省苏北人民医院 | 一种胃癌分化相关标志物miRNA组合物及其芯片和应用 |
US11099150B1 (en) | 2019-08-27 | 2021-08-24 | Qingdao University | Method for preparing ratiometric electrochemical miR3123 aptasensor based on metal-organic framework composite |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101798595A (zh) * | 2010-03-08 | 2010-08-11 | 江其生 | 一种新的miRNA检测技术及其应用 |
CN103205423A (zh) * | 2013-04-11 | 2013-07-17 | 百瑞德(南京)生物科技有限公司 | 一种前列腺癌生物标志物miR-126-5P、诊断试剂盒及应用 |
-
2014
- 2014-12-19 CN CN201410791924.8A patent/CN104531856A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101798595A (zh) * | 2010-03-08 | 2010-08-11 | 江其生 | 一种新的miRNA检测技术及其应用 |
CN103205423A (zh) * | 2013-04-11 | 2013-07-17 | 百瑞德(南京)生物科技有限公司 | 一种前列腺癌生物标志物miR-126-5P、诊断试剂盒及应用 |
Non-Patent Citations (2)
Title |
---|
DABEI TANG 等: "The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer", 《CLINICAL BIOCHEMISTRY》, vol. 46, 13 February 2013 (2013-02-13), pages 926 - 932, XP028559523, DOI: 10.1016/j.clinbiochem.2013.01.027 * |
MUNENORI TAKAOKA等: "Heparanase Expression Correlates with Invasion and Poor Prognosis in Gastric Cancers", 《LABORATORY INVESTIGATION》, vol. 83, no. 5, 31 May 2003 (2003-05-31), pages 613 - 622 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110577999A (zh) * | 2019-08-02 | 2019-12-17 | 上海交通大学 | 一种cxcr4作为胃癌预后评估生物标志物的应用及诊断试剂盒 |
US11099150B1 (en) | 2019-08-27 | 2021-08-24 | Qingdao University | Method for preparing ratiometric electrochemical miR3123 aptasensor based on metal-organic framework composite |
CN111621573A (zh) * | 2020-07-27 | 2020-09-04 | 江苏省苏北人民医院 | 一种胃癌分化相关标志物miRNA组合物及其芯片和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Giannopoulou et al. | Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes | |
CN107043823B (zh) | 一种结直肠癌相关的肿瘤标志物及应用 | |
Wang et al. | Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis | |
Wang et al. | Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer | |
US20150011414A1 (en) | Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples | |
Quirico et al. | The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies | |
Selth et al. | Circulating microRNAs: macro-utility as markers of prostate cancer? | |
CN109182521B (zh) | circRNA作为甲状腺乳头状癌标志物的应用 | |
Cheung et al. | The potential of circulating cell free RNA as a biomarker in cancer | |
Kong et al. | Clinical significance of serum miR-25 as a diagnostic and prognostic biomarker in human gastric cancer | |
JPWO2013038737A1 (ja) | 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ | |
Gao et al. | Prognostic value of microRNAs in colorectal cancer: a meta-analysis | |
CN105018638A (zh) | 胃癌发生相关分子标志物lncRNA HOTTIP的检测及应用 | |
Katseli et al. | Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers | |
Monnaka et al. | Overview of miRNAs for the non-invasive diagnosis of endometriosis: evidence, challenges and strategies. A systematic review | |
Chen et al. | miR‑224/miR‑141 ratio as a novel diagnostic biomarker in renal cell carcinoma | |
Cui et al. | Upregulation of microRNA 181c expression in gastric cancer tissues and plasma | |
Bilal et al. | An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs | |
CN101613748A (zh) | 一种检测胰腺癌血清标志物的方法 | |
Hoey et al. | Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies | |
Ghanbari et al. | Expression Analysis of Previously Verified Fecal and Plasma Down-regulated MicroRNAs (miR-4478, 1295-3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients. | |
CN104531856A (zh) | 胃癌进展及预后相关分子标志物miR-1258 | |
CN106191055A (zh) | 一种非小细胞肺癌标志物、检测试剂及试剂盒 | |
CN105018639A (zh) | 胃癌预后新型分子标志物lncRNA-AB007962的检测及用途 | |
CN103074431B (zh) | 检测结直肠癌血清miRNA-128的专用引物、试剂盒及方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150422 |